Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Clinically Isolated Syndrome Clear all
Terminated No phase listed Observational

Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

NCT03926637
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Multiple Sclerosis Performance Test (MSPT)
Other
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
3,073 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
22
States / cities
Berkeley, California • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

NCT00622700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 6, 2026, 4:51 PM EDT
Active, not recruiting Not applicable Interventional

Autoimmune Intervention Mastery Course Study

NCT05057676
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, Fibromyalgia, Post Acute Sequelae of COVID-19, Cancer in Remission With Persisting Fatigue
Interventions
Immediate Autoimmune Intervention Mastery Course (AIM), Immediate Question and Answer sessions. (AIM Q and A sessions), Delayed Autoimmune Intervention Mastery Course (delayed AIM course), Delayed AIM Question and Answer sessions
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Biobank For MS And Other Demyelinating Diseases

NCT00445367
View directory record Official record
Conditions
Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
Interventions
Not listed
Lead sponsor
Accelerated Cure Project for Multiple Sclerosis
Other
Eligibility
Not listed
Enrollment
3,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2036
U.S. locations
10
States / cities
Phoenix, Arizona • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 6, 2026, 4:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

MS-ResearchBiomarkerS

NCT05204459
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2041
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

NCT06526000
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

NCT00616733
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
CS-0777 tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Denver, Colorado • Port Orange, Florida • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Sep 6, 2026, 4:51 PM EDT
Active, not recruiting Phase 4 Interventional

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

NCT04466150
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Prebiotic vs Probiotic in Multiple Sclerosis

NCT04038541
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Interventions
Prebiotics (Prebiotin Prebiotic Fiber Stick Pac), Probiotics (Visbiome®)
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Not listed No phase listed Observational

Risk Factors in Early Multiple Sclerosis

NCT03586986
View directory record Official record
Conditions
Multiple Sclerosis, Magnetic Resonance Imaging, Biomarkers, Clinically Isolated Syndrome, Radiologically Isolated Syndrome
Interventions
Brain MRI
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years
Enrollment
300 participants
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational

Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice

NCT06737419
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

NCT00094172
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 6, 2026, 4:51 PM EDT
Not listed No phase listed Observational

Clinical Importance of Glucose Regulation in Relapsing MS

NCT03004079
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 59 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 6, 2026, 4:51 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

NCT06220669
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
LY3541860, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Gulf Breeze, Florida • Winter Park, Florida • Northbrook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gene Expression Profiles in Multiple Sclerosis (MS)

NCT00704834
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood Draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

NCT04998812
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

NCT04998851
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT06065670
View directory record Official record
Conditions
Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 2 Interventional

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis

NCT00245622
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Tovaxin Autologous T cell vaccine, Placebo
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
33
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

NCT06395909
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

NCT06940323
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, NMOSD, Myasthenia Gravis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis

NCT01396343
View directory record Official record
Conditions
Pediatric Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 21 Years
Enrollment
1,276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • San Bernardino, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 6, 2026, 4:51 PM EDT
Active, not recruiting Not applicable Interventional

Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis

NCT04009005
View directory record Official record
Conditions
Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis
Interventions
Therapeutic diet and lifestyle
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS

NCT00617383
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 6, 2026, 4:51 PM EDT